Cabotegravir: 10 agencies, 2020–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 5.4 years, from 12 Nov 2020 at AWMSG (Wales) to 28 Apr 2026 at AIFA (Italy).
CIPM (Spain) changed its position: not recommended on 2 Jun 2022, recommended by 25 Feb 2026, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for cabotegravir, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 15 of 25 records date from 2023 or later.
The programme is broad: 10 distinct indication wordings are recorded for cabotegravir by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
5 of these 25 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess cabotegravir, on 12 Nov 2020; AIFA (Italy) did not open a file until 28 Apr 2026 — a wide spread of 5.4 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 7 years in total.
7 of the 10 agencies here assessed cabotegravir more than once, CIPM (Spain) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for cabotegravir.
The full ledger for cabotegravir reads 9 recommended, 5 not recommended, 3 no benefit and 3 restricted, with 5 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 25 Feb 2026 | Indicación terapéutica autorizada: Apretude está indicado, en combinación con prácticas sexuales más seguras, para la pr… | financed by the SNS · art. 92 a, c | source |
| NICE (England) | 5 Nov 2025 | NICE TA1106 | recommended (optimised) | source |
| G-BA (Germany) | 7 Aug 2025 | Vocabria — benefit assessment §35a | added benefit: not proven | source |
| PBAC (Australia) | 2023 | Pre-exposure prophylaxis for human immunodeficiency virus (HIV) infection | Deferred | source |
| HAS (France) | 21 Apr 2021 | Listing (Transparency Committee) | SMR insufficient · ASMR V | source |
20 further decisions for cabotegravir, across 10 agencies, are not shown here. They include the most recent record on file, 28 Apr 2026 from AIFA (Italy); its outcome is in the subscriber dataset. They link to 14 further source documents.
Related molecules
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- raltegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
- darunavir — same ATC class J05A — Antivirals
- dolutegravir — same ATC class J05A — Antivirals
Coverage: 25 decisions for cabotegravir from 10 agencies, 2020 to 2026. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.